Neurooncology Committee Meeting Agenda

Chair: Evanthia Galanis, MD

Welcome – Overview

Newly Diagnosed GBM

Active Protocols
A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation

J. Sarkaria

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 in Newly Diagnosed Glioblastoma Following Resection and Chemoradiation

P. Wen

Phase I/II Study of AZD1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma

B. Alexander

Recently Completed Trials
N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA]Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Recurrent GBM

A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) – Closed (2/21/17) following interim analysis

O. Bloch

I. Parney
Recently Completed Trials
N1174: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Accrual goal met 9/4/2015)

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14)

Approved Concepts in Development
A071702: A Phase II Study of Anti-PD-1/PD-L1 Blockade Immunotherapy in Patients with Hypermutated Recurrent Glioblastoma G. Dunn E. Galanis D. Reardon

New Concepts
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma K. Schmainda

Anaplastic Gliomas – Newly Diagnosed
Active Protocols
N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma K. Jaeckle E. Galanis

Recently Completed Trials
EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial

Low Grade Gliomas
E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (Temp. Closed)

Meningiomas
A071401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations P. Brastianos

Craniopharyngiomas
A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas P. Brastianos
**Symptom Control**
A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis after Radiosurgery: A Randomized Phase II Trial C. Chung

**Leptomeningeal Metastases**

**Approved Concepts in Development**
A Randomized Open-Label, Multi-Center Study of ANG1005 Compared with Physician’s Best Choice in Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases P. Kumthekar

**Brain Metastases**
CE.7: A Phase III Trial of Radiosurgery (SRS) vs. WBRT for Multiple (5-15) Brain Metastases M. Chan

**Approved Concepts in Development**
A071701: Molecularly-driven trial in brain metastases P. Brastianos

**Recently Completed Trials**
N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (Brown and al, JAMA 2016)